Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Portfolio Pulse from
Allogene Therapeutics published data from its Phase 1 ALPHA/ALPHA2 trials of the allogeneic CAR T product, cemacabtagene ansegedleucel, in relapsed/refractory large B-cell lymphoma. The results, published in the Journal of Clinical Oncology, show durable responses with the longest follow-up to date.
February 13, 2025 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics announced positive Phase 1 trial results for its CAR T product, cemacabtagene ansegedleucel, in large B-cell lymphoma, published in a leading oncology journal.
The publication of positive trial results in a reputable journal is likely to boost investor confidence in Allogene Therapeutics, potentially leading to a short-term increase in stock price. The data represents significant progress in the treatment of large B-cell lymphoma, a key area for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100